EuBiologics (A206650) Stock Overview
A biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A206650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
EuBiologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,180.00 |
| 52 Week High | ₩17,700.00 |
| 52 Week Low | ₩10,000.00 |
| Beta | 0.49 |
| 1 Month Change | 12.61% |
| 3 Month Change | 23.62% |
| 1 Year Change | 28.10% |
| 3 Year Change | 110.25% |
| 5 Year Change | -21.95% |
| Change since IPO | 199.41% |
Recent News & Updates
Shareholder Returns
| A206650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.3% | 11.1% | 10.8% |
| 1Y | 28.1% | 38.5% | 110.1% |
Return vs Industry: A206650 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A206650 underperformed the KR Market which returned 110.1% over the past year.
Price Volatility
| A206650 volatility | |
|---|---|
| A206650 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in KR Market | 15.3% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A206650 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A206650's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Yeong-Ok Baik | eubiologics.com |
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules.
EuBiologics Co., Ltd. Fundamentals Summary
| A206650 fundamental statistics | |
|---|---|
| Market cap | ₩534.32b |
| Earnings (TTM) | ₩24.87b |
| Revenue (TTM) | ₩96.04b |
Is A206650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206650 income statement (TTM) | |
|---|---|
| Revenue | ₩96.04b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩96.04b |
| Other Expenses | ₩71.17b |
| Earnings | ₩24.87b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 677.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 25.89% |
| Debt/Equity Ratio | 0.0% |
How did A206650 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 08:26 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EuBiologics Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyun Dong Sung | KB Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |